With Dr Eli Kotler and Prof Dr Karl J. Friston (UK)
Date: Wed 09 June 2021 @ 7:30pm
Location: Online
Why do certain drugs have such a profound effect on how we make sense of the world? In this webinar, we will look at the brain as an organ of sentience – assimilating sensory information to update its beliefs about states of affairs beyond our sensory veils. In particular, we will consider perception in terms of inference or hypothesis testing. In other words, we will look at the brain as a little scientist, who uses sensory evidence to confirm or disconfirm her hypotheses about how the sensorium is caused.
This way of formalising brain function allows us to talk about beliefs and belief-updating in a way that can be connected to message passing among different brain systems. This is important because drugs can have a profound influence on this message passing. Our focus will be on how we attend to different streams of sensory information – or different levels of abstraction. This attention is thought to be mediated by the selection or enabling of connections in the brain that allow newsworthy information to be passed from the sensory brain to the deep hierarchical levels of processing and representation. This means that certain drugs can exert a profound effect on the ensuing perceptual synthesis.
Furthermore, we can start to understand psychopathology in terms of false inference. For example, believing something is there when it is not (i.e., a hallucination or delusion) or believing something is not there when it is (i.e., attentional neglect or agnosia). Further examples include the fears of abandonment in borderline states, the self-deprecation of depression and the constant fears of post-traumatic conditions. This webinar provides an introduction the hierarchical, Bayesian and anarchic brain. It offers a formal and intuitive account of the effect of psychedelic and psychometric drugs – and how they affect the message passing in the brain underwrites our beliefs about the lived world – and the way we engage with that world.
WEBINAR SESSION
Date: Wednesday 9 June 2021
Time: 7:25pm for 7:30pm start – 8:45pm (incl Q&A) (AEST)
The presentation WILL BEGIN AT 7:30pm.
Location: Online. A link will be emailed to you with the viewing details.
Support these events:
Whilst our webinars are free of charge, we strongly encourage you to make a donation and support our important mission of making these therapies available through our medical system. This can be done at the time of reserving your ticket. Please share these events with your networks.
More about medicinal psychedelic treatments:
Psychedelic-assisted treatments offer enormous potential in providing a meaningful alternative to current treatments for mental illness. PTSD is a debilitating condition that affects tens of millions of people worldwide, with many more trauma victims diagnosed with comorbid conditions such as depression, anxiety and eating disorders. In recent clinical trials, MDMA has been shown to produce reliable clinical improvements, restoring patient safety and self-agency even for individuals who have suffered with PTSD for many years, and for whom many treatments have failed.
The wave of clinical psychedelic research and regulatory support is rapidly building, with experts forecasting the availability of psychedelic-assisted treatments in the US and EU within the next 2 to 5 years, subject to positive clinical outcomes in large trials that are currently underway.
MBBS MPM FRANZCP Cert. Old Age Psych. AFRACMA
Eli is a consultant psychiatrist and psychodynamic psychotherapist. He is the Medical Director of Malvern Private Hospital, an addiction and trauma hospital in Melbourne. Eli completed the inaugural CPAT course, and has since been on its faculty. He was appointed as the course’s Australian Course Director in 2023.
As a psychiatric trainee, Eli was awarded the Royal College of Psychiatrists Trainee Prize for his Scholarly Project on Depression, as well as a Research Committee Trainee award for his work on Philosophy of Mind. As an adjunct lecturer at Monash University, he oversees medical students on their addiction medicine rotation, and sneaks in lectures on Philosophy of Mind, Psychodynamic Psychiatry and Psychedelic Assisted Therapies (PAT). He has been invited as a key-note speaker by the RANZCP and International Psychoanalytic Association to lecture on PAT. He has been invited by the Victorian Government to design new addiction programs and works with the AFL players association.
Eli is an Associate Fellow of the Royal Australasian College of Medical Administrators, and is a member of the Australasian Professional Society on Alcohol and other Drugs. He also has extensive research experience with novel therapeutics for neurodegenerative diseases. He sits on the Victorian Medical Panels, and is an expert witness in historical abuse cases.
Clinically, Eli works in a psychodynamic framework, and attempts to help his patients find freedom from their addictions and trauma through relational experiences, and experiential self-awareness. He is actively treating patients in Australia with MDMA-assisted therapy.
MBBS, MA, MRCPsych, MAE, FMedSci, FRBS, FRS
Karl Friston is a theoretical neuroscientist and authority on brain imaging. He invented statistical parametric mapping (SPM), voxel-based morphometry (VBM) and dynamic causal modelling (DCM). These contributions were motivated by schizophrenia research and theoretical studies of value-learning, formulated as the dysconnection hypothesis of schizophrenia. Mathematical contributions include variational Laplacian procedures and generalized filtering for hierarchical Bayesian model inversion.
Friston currently works on models of functional integration in the human brain and the principles that underlie neuronal interactions. His main contribution to theoretical neurobiology is a free-energy principle for action and perception (active inference). Friston received the first Young Investigators Award in Human Brain Mapping (1996) and was elected a Fellow of the Academy of Medical Sciences (1999). In 2000 he was President of the international Organization of Human Brain Mapping. In 2003 he was awarded the Minerva Golden Brain Award and was elected a Fellow of the Royal Society in 2006. In 2008 he received a Medal, College de France and an Honorary Doctorate from the University of York in 2011.
He became of Fellow of the Royal Society of Biology in 2012, received the Weldon Memorial prize and Medal in 2013 for contributions to mathematical biology and was elected as a member of EMBO (excellence in the life sciences) in 2014 and the Academia Europaea in (2015). He was the 2016 recipient of the Charles Branch Award for unparalleled breakthroughs in Brain Research and the Glass Brain Award, a lifetime achievement award in the field of human brain mapping. He holds Honorary Doctorates from the University of Zurich and Radboud University.
Disclaimer: Mind Medicine Australia does not encourage or facilitate illegal use of psychedelics or plant medicines. MMA focus is focused on clinical and legal use only supported by the emerging science and legislative processes. Mind Medicine Australia reserves the right to record and publish webinars on various social media platforms. You agree that you will not discuss any names, locations or specific details of illegal use of psychedelics both verbally or via any written forms of communication via Mind Medicine Australia social media platforms (for example Facebook, Instagram or Zoom private and public chat forms during a webinar). Breaches of these guidelines may result in not being able to participate in the event. We thank you for support and cooperation on these matters.
